Authors: SHEETS RL GOLDENTHAL KL

Citation: Rl. Sheets et Kl. Goldenthal, TRADITIONAL APPROACH PREVENTIVE HIV VACCINES - WHAT ARE THE CELL SUBSTRATE AND INACTIVATION ISSUES, AIDS research and human retroviruses, 14(7), 1998, pp. 627-633

Authors: HEYWARD WL MACQUEEN KM GOLDENTHAL KL

Citation: Wl. Heyward et al., HIV VACCINE DEVELOPMENT AND EVALUATION - REALISTIC EXPECTATIONS, AIDS research and human retroviruses, 14, 1998, pp. 205-210

Authors: GOLDENTHAL KL VAILLANCOURT JM GEBER A LUCEY DR

Citation: Kl. Goldenthal et al., PREVENTIVE HIV TYPE-1 VACCINE CLINICAL-TRIALS - A REGULATORY PERSPECTIVE, AIDS research and human retroviruses, 14, 1998, pp. 333-340

Authors: SMITH HA GOLDENTHAL KL VOGEL FR RABINOVICH R AGUADO T

Citation: Ha. Smith et al., WORKSHOP ON THE CONTROL AND STANDARDIZATION OF NUCLEIC-ACID VACCINES - 8 FEBRUARY 1996, NATCHER-CONFERENCE-CENTER, BETHESDA, MD, Vaccine, 15(8), 1997, pp. 931-933

Authors: HENCHAL LS MIDTHUN K GOLDENTHAL KL

Citation: Ls. Henchal et al., SELECTED REGULATORY AND SCIENTIFIC TOPICS FOR CANDIDATE ROTAVIRUS VACCINE DEVELOPMENT, The Journal of infectious diseases, 174, 1996, pp. 112-117

Authors: GOLDENTHAL KL CAVAGNARO JA ALVING CR VOGEL FR

Citation: Kl. Goldenthal et al., SAFETY EVALUATION OF VACCINE ADJUVANTS - PERATIVE-VACCINE-DEVELOPMENT-MEETING-WORKING-GROUP, AIDS research and human retroviruses, 9, 1993, pp. 190000047-190000051